```html

Zollinger‑Ellison Syndrome – Ulcerative Type

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder in which one or more gastrin‑producing neuroendocrine tumors (called gastrinomas) develop in the pancreas or duodenum. The excess gastrin stimulates the stomach to release large amounts of gastric acid, leading to multiple, recurrent peptic ulcers—hence the term “ulcerative type.”

Who is affected? ZES can occur at any age but most often presents in adults aged 30–60 years. Both men and women are affected, with a slight male predominance (≈55 %). About 25 % of cases are associated with the inherited condition multiple endocrine neoplasia type 1 (MEN‑1).

Prevalence: The overall incidence is estimated at **1–3 cases per million people per year** and a prevalence of roughly **0.1 %** among patients with peptic ulcer disease (PUD) (Mayo Clinic, 2024). Because the condition is rare and symptoms overlap with more common ulcers, it is often under‑diagnosed.

Symptoms

The hallmark of the ulcerative type is the development of multiple, refractory gastric or duodenal ulcers. Symptoms can be intermittent and vary in intensity.

• Abdominal pain – burning or gnawing pain usually in the epigastrium, often worse 1–3 h after meals.
• Acid reflux / heartburn – persistent heartburn that does not improve with over‑the‑counter antacids.
• Nausea and vomiting – especially after eating; vomiting may contain bile.
• Diarrhea – acidic stomach contents can inactivate pancreatic enzymes, leading to malabsorption.
• Weight loss – due to chronic diarrhea, malabsorption, and reduced food intake.
• Gastrointestinal bleeding – melena or hematemesis from ulcer erosion.
• Perforated ulcer – sudden severe abdominal pain, rigidity, and signs of peritonitis.
• Gastroparesis – delayed gastric emptying caused by acid injury to the stomach wall.
• Refractory ulcers – ulcers that do not heal despite standard proton‑pump inhibitor (PPI) therapy.

In patients with MEN‑1, extra‑pancreatic manifestations such as hyperparathyroidism or pituitary adenomas may also be present.

Causes and Risk Factors

Primary cause

ZES is caused by gastrin‑secreting neuroendocrine tumors (gastrinomas). These are usually small (<2 cm) but can be malignant in 20–25 % of sporadic cases and up to 50 % when associated with MEN‑1.

Risk factors

• Genetic predisposition – presence of MEN‑1 mutation (mutations in the MEN1 gene).
• Family history – first‑degree relatives with MEN‑1 or a known gastrinoma.
• Chronic H. pylori infection – may coexist and exacerbate ulcer formation, though it does not cause ZES.
• Age & sex – most frequent in middle‑aged adults; slight male predominance.

Diagnosis

Because the symptoms mimic common peptic ulcer disease, a high index of suspicion is essential—especially when ulcers are multiple, atypical in location (e.g., distal duodenum), or refractory to PPIs.

Step‑by‑step diagnostic pathway

1. Clinical assessment – detailed history (ulcer recurrence, family history of MEN‑1) and physical exam.
2. Laboratory tests
   • Fasting serum gastrin level – values > 1000 pg/mL are highly suggestive; levels 2–5 × upper limit of normal (ULN) may be seen in other conditions.
   • Secretin stimulation test – paradoxical rise in gastrin after IV secretin is diagnostic for gastrinoma.
   • Stool occult blood – to screen for bleeding.
3. Imaging studies
   • Endoscopic ultrasound (EUS) – highly sensitive (≈80 %) for small pancreatic gastrinomas.
   • Somatostatin receptor scintigraphy (Octreoscan) or Gallium‑68 DOTATATE PET/CT – detects metastatic disease and extra‑pancreatic lesions.
   • CT/MRI abdomen – identifies larger tumors and liver metastases.
4. Upper endoscopy (EGD) – visualizes the characteristic multiple ulcers, especially beyond the duodenal bulb.
5. Genetic testing – recommended for patients with MEN‑1 features or a family history.

Reference: National Institutes of Health (NIH) Neuroendocrine Tumor Guidelines, 2023; [NIH 2023]

Treatment Options

Therapy aims to control acid hypersecretion, eradicate or control the tumor, and manage complications.

Acid‑Suppressive Medications

• High‑dose Proton Pump Inhibitors (PPIs) – omeprazole 60–120 mg/day or equivalent; most effective for ulcer healing.
• Potassium‑competitive acid blockers (P‑CABs) – e.g., vonoprazan (available in some regions) offers rapid, sustained acid suppression.
• Medication should be continued indefinitely unless the tumor is removed and acid production normalizes.

Surgical Management

• Localized gastrinoma – enucleation or pancreaticoduodenectomy; surgical cure rates up to 80 % for tumors ≤ 2 cm without metastasis.
• Metastatic disease – debulking surgery, hepatic resection, or liver‑directed therapies (radiofrequency ablation, embolization).
• In MEN‑1 patients, surgery is more complex; a tailored approach balancing tumor control and pancreatic function is required.

Medical Therapies for Tumor Control

• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin release and may shrink tumors.
• Targeted therapies – everolimus or sunitinib are approved for progressive neuroendocrine tumors.
• Peptide receptor radionuclide therapy (PRRT) – ^177Lu‑DOTATATE for somatostatin‑receptor positive disease.

Lifestyle & Supportive Measures

• Avoid NSAIDs, aspirin, and other ulcer‑promoting drugs.
• Eat small, frequent meals; limit foods that trigger reflux (citrus, fatty meals, caffeine, alcohol).
• Maintain adequate hydration; consider oral rehydration solutions if diarrhea is severe.
• Supplementation of fat‑soluble vitamins (A, D, E, K) if malabsorption is present.

Living with Zollinger‑Ellison Syndrome – Ulcerative Type

Management is lifelong and multidisciplinary.

• Medication adherence – Never skip PPIs; set daily reminders.
• Regular monitoring – Check gastrin levels and imaging every 6–12 months (or sooner if symptoms change).
• Nutrition – Work with a dietitian to create a low‑acid, low‑fat diet that meets caloric needs.
• Stress management – Stress can exacerbate ulcer pain; techniques such as mindfulness, yoga, or counseling are beneficial.
• Vaccinations – If you undergo splenectomy or have liver metastases, keep hepatitis A/B and pneumococcal vaccines up to date.
• Support groups – Connecting with other patients (e.g., via the Carcinoid Cancer Foundation) can provide practical tips and emotional support.

Prevention

Because most cases are sporadic and arise from genetic mutations, primary prevention is limited. However, some measures can reduce the risk of ulcer complications:

• Eradicate Helicobacter pylori if present – testing and appropriate antibiotic therapy.
• Avoid chronic use of ulcerogenic medications (NSAIDs, steroids).
• Adopt a balanced diet low in processed foods and high in fiber.
• For individuals with MEN‑1, genetic counseling and early screening for gastrinomas are recommended.

Complications

If untreated or poorly controlled, ZES can lead to serious health problems:

• Bleeding ulcers – may require endoscopic hemostasis or blood transfusion.
• Perforation – surgical emergency with risk of sepsis.
• Gastrointestinal obstruction – from ulcer scarring or tumor mass effect.
• Metastatic disease – liver is the most common site; reduces survival.
• Malabsorption & nutritional deficiencies – chronic diarrhea can cause electrolyte abnormalities and vitamin deficiencies.
• Refractory gastro‑esophageal reflux disease (GERD) – may progress to Barrett’s esophagus.

When to Seek Emergency Care

---

Sources:

• Mayo Clinic. “Zollinger‑Ellison syndrome.” Updated 2024. https://www.mayoclinic.org
• National Institutes of Health. “Neuroendocrine Tumors Guidelines.” 2023. https://www.cancer.gov
• Cleveland Clinic. “Management of Gastrinomas.” 2023. https://my.clevelandclinic.org
• World Health Organization. “Classification of Neuroendocrine Tumors.” 2022. https://www.who.int
• American College of Gastroenterology. “Guidelines for Diagnosis and Management of Peptic Ulcer Disease.” 2023. https://gi.org

```